Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

Sunshine Biopharma logo
$1.26 -0.01 (-0.39%)
As of 10:25 AM Eastern

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Key Stats

Today's Range
$1.26
$1.31
50-Day Range
$1.22
$2.39
52-Week Range
$1.17
$23.20
Volume
27,437 shs
Average Volume
602,504 shs
Market Capitalization
$3.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

Sunshine Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

SBFM MarketRank™: 

Sunshine Biopharma scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sunshine Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Sunshine Biopharma has received no research coverage in the past 90 days.

  • Read more about Sunshine Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Sunshine Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    3.78% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 13.66%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sunshine Biopharma does not currently pay a dividend.

  • Dividend Growth

    Sunshine Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.78% of the float of Sunshine Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Sunshine Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sunshine Biopharma has recently decreased by 13.66%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sunshine Biopharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Sunshine Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for SBFM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of Sunshine Biopharma is held by insiders.

  • Percentage Held by Institutions

    41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sunshine Biopharma's insider trading history.
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBFM Stock News Headlines

Sunshine Biopharma launches Everolimus in Canada
Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
See More Headlines

SBFM Stock Analysis - Frequently Asked Questions

Sunshine Biopharma's stock was trading at $3.00 at the beginning of the year. Since then, SBFM stock has decreased by 57.8% and is now trading at $1.2650.
View the best growth stocks for 2025 here
.

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of $9.00 by $9.94. The company had revenue of $8.44 million for the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 17.89% and a negative net margin of 12.82%.

Shares of Sunshine Biopharma reverse split on the morning of Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/05/2024
Today
5/08/2025
Next Earnings (Estimated)
5/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SBFM
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+1,085.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,510,000.00
Pretax Margin
-12.48%

Debt

Sales & Book Value

Annual Sales
$34.87 million
Price / Cash Flow
N/A
Book Value
$1,651.69 per share
Price / Book
0.00

Miscellaneous

Free Float
1,223,000
Market Cap
$3.42 million
Optionable
Not Optionable
Beta
1.35
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SBFM) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners